Other Information.
−Removed: (c) During the three months ended March 31, 2026, no director or officer (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted or terminated a “ Rule 10b5-1 trading arrangement” and/or “ non-Rule 10b5-1 trading arrangement,” as each term is defined in item 408 of Regulation S-K.
+Added: (c) On May 14, 2026 , Kumar Budur , Chief Medical and Scientific Officer of the Company, adopted a Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of (i) up to 61,406 shares of the Company’s common stock related to the to the exercise of options, (ii) up to 9,995 shares of the Company’s common stock related to the vesting of restricted stock units previously granted, and (iii) up to 1,005 shares of the Company’s common stock related the Company’s employee stock purchase plan, beginning on August 13, 2026, and continuing until June 30, 2027.
+Added: On June 5, 2026 , this plan entered into on May 14, 2026 , was subsequently terminated and Kumar Budur adopted a new Rule 10b5-1 trading arrangement that is intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of (i) up to 61,406 shares of the Company’s common stock related to the to the exercise of options, (ii) up to 9,995 shares of the Company’s common stock related to the vesting of restricted stock units previously granted, and (iii) up to 1,005 shares of the Company’s common stock related the Company’s employee stock purchase plan, beginning on September 4, 2026, and continuing until June 30, 2027 .
Incorporated by Reference
15 unchanged sentences
April 14, 2026
+Added: Separation Agreement between Harmony Biosciences Management, Inc.
+Added: and Glenn Reicin, dated July 16, 2026.
+Added: July 16, 2026
Certification of Chief Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
4 unchanged sentences
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: The following financial statements from the Company ’ s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026, formatted in Inline XBRL:
+Added: The following financial statements from the Company ’ s Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2026, formatted in Inline XBRL:
(i) Balance Sheets, (ii) Statements of Operations, (iii) Statements of Stockholders ’ Equity and (vi) Notes to Financial Statements, tagged as blocks of text and including detailed tags.
12 unchanged sentences
President, Chief Executive Officer and Director (principal executive officer)
−Removed: /s/ Glenn Reicin
−Removed: Chief Financial Officer (principal financial officer)
+Added: August 4, 2026
+Added: /s/ Stephen Mollichella
+Added: Stephen Mollichella
+Added: Senior Vice President, Controller and Interim Principal Financial Officer (principal financial officer)
+Added: August 4, 2026
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.